Share Price, page-8831

Funding the Trofinetide Phase 3 trial cost ~$300M.

We partnered with Acadia because of the substantial synergies. Acadia had the bandwidth, the experienced trial expertise, the US relationships with both the trial sites and the FDA to make it happen. Acadia put together the significant marketing and communication team to make the launch successful.

It's naive to think that NEU can easily replicate the Acadia effort in a timely fashion (especially if the goal is to treat sufferers).

The middle way is to partner with a capable company (like Acadia has shown itself to be), with NEU funding the studies. That would get the trial completed, and enable NEU to secure a greater sales revenue share.